Mar 20, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Miguel Weil from Department of Cell Research and Immunology at the Tel Aviv University on a clinical proteomics project focusing on leveraging our Complete360 body fluid proteomics assays for clinical discoveries.
Feb 28, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in the academic journal CANCERS, presenting a new pipeline developed for validating and absolutely quantifying neoantigens from very limited amount of clinical samples.
Feb 26, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Dr. Luis Marques da Costa and his team from Lisbon School of Medicine on a clinical proteomics project focusing on leveraging our Complete360 body fluid proteomics assays for clinical discoveries.
Feb 07, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Sumati Gupta and her team from University of Utah Huntsman Cancer Institute on a clinical proteomics project focusing on leveraging our Complete360 proteomics assays for clinical discoveries.
Jan 29, 2022 | BALTIMORE – Complete Omics Inc, a multi-omics molecular diagnostics company, today announces the publication of a new peer reviewed paper in Science Advances journal, demonstrating the value of targeting antigens derived from human endogenous retroviruses (HERVs) specifically overexpressed by tumor cells for new immunotherapy approaches.
Jan 19, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Andras Attila Heczey and his team from Baylor College of Medicine on a clinical proteomics project focusing on leveraging our Complete360 body fluid proteomics assays for clinical discoveries.
Jan 12, 2022 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Marco Sardiello and his team from Washington University in St. Louis on a clinical proteomics project focusing on using Complete360 platform for identifying novel biological mechanisms.
December 23, 2021 | BALTIMORE –
Dear Team Members and Friends:
2021 has been an exciting year for Complete Omics – – we brought dramatic improvements to biomedical sciences and patient care by advancing our multi-omics molecular diagnostic pipelines even further. In the year of 2021, over 80 new research papers featuring Complete Omics’ technologies and platforms have been published.
Since 2021 summer, Complete Omics started to offer cutting-edge multi-omics research services backed up by our top profile publications and patents. Now we are thrilled to work with over 30 pharmaceutical corporations and over 50 research labs worldwide to implement our Complete360® multi-omics molecular diagnostic pipeline and our Valid-NEOTM companion diagnostics pipeline. Hundreds of novel biomarkers and dozens of new drug targets are identified and quantified by us, and numerous treatment approaches are being developed based on our discoveries.
We expect massive new features to be added on to our platforms over the next few years, and many exciting new discoveries ahead from ourselves and from the collaborations with scientists throughout the world.
Please follow our company’s progress or contact us at info@completeomics.com to learn more about how we can advance your research and patient care.
All of us at Complete Omics wish you a Merry Christmas and Happy New Year of 2022!
Dec 10, 2021 | BALTIMORE – Complete Omics’ Clinical Genomics team announced a collaboration with Dr. Rebecca Morris on several single cell omics analysis projects
Nov 19, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Generate Biomedicines on a series of immunopeptidomics projects. On Nov 18 2021, Generate Biomedicines just announced a Series B financing of $370 million to advance its protein-targeted drug generation platform.
